{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:42:46Z","timestamp":1786545766760,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1038\/s41395-018-0108-6","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T10:31:45Z","timestamp":1529404305000},"page":"1206-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD"],"prefix":"10.14309","volume":"113","author":[{"given":"Laura E.","family":"Targownik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Lix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210404","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s00198-016-3631-6","article-title":"The current economic burden of illness of osteoporosis in Canada.","volume":"27","author":"Hopkins","year":"2016","journal-title":"Osteoporos Int"},{"key":"R2-19-20210404","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/bmj.303.6808.961","article-title":"Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.","volume":"303","author":"Hansen","year":"1991","journal-title":"BMJ"},{"key":"R3-19-20210404","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohns disease with 6-mercaptopurine. A long-term, randomized, double-blind study.","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"key":"R4-19-20210404","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohns disease.","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"R5-19-20210404","first-page":"CD000478","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.","volume":"5","author":"Timmer","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-19-20210404","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohns disease. North American Crohns Study Group Investigators.","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"R7-19-20210404","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/gast.1996.v110.pm8613046","article-title":"Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial.","volume":"110","author":"Oren","year":"1996","journal-title":"Gastroenterology"},{"key":"R8-19-20210404","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.crohns.2011.03.012","article-title":"Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy.","volume":"5","author":"Manosa","year":"2011","journal-title":"J Crohns Colitis"},{"key":"R9-19-20210404","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.gastro.2015.10.050","article-title":"Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis.","volume":"150","author":"Carbonnel","year":"2016","journal-title":"Gastroenterology"},{"key":"R10-19-20210404","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1038\/ajg.2009.387","article-title":"Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohns disease.","volume":"104","author":"Picco","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R11-19-20210404","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohns disease.","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"R12-19-20210404","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"R13-19-20210404","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease: an open randomised trial.","volume":"371","author":"DHaens","year":"2008","journal-title":"Lancet"},{"key":"R14-19-20210404","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","article-title":"Mucosal healing predicts sustained clinical remission in patients with early-stage Crohns disease.","volume":"138","author":"Baert","year":"2010","journal-title":"Gastroenterology"},{"key":"R15-19-20210404","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.","volume":"133","author":"Froslie","year":"2007","journal-title":"Gastroenterology"},{"key":"R16-19-20210404","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.crohns.2014.02.022","article-title":"Improving quality of care in inflammatory bowel disease: what changes can be made today?","volume":"8","author":"Panes","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R17-19-20210404","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"key":"R18-19-20210404","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study.","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"key":"R19-19-20210404","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/oxfordjournals.aje.a009735","article-title":"Epidemiology of Crohns disease and ulcerative colitis in a central Canadian province: a population-based study.","volume":"149","author":"Bernstein","year":"1999","journal-title":"Am J Epidemiol"},{"key":"R20-19-20210404","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cgh.2012.10.038","article-title":"Long-term outcome of patients with Crohns disease that responds to azathioprine.","volume":"11","author":"Camus","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R21-19-20210404","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cgh.2017.01.035","article-title":"Temporal trends in initiation of therapy with tumor necrosis factor antagonists for patients with inflammatory bowel disease: a population-based analysis.","volume":"15","author":"Targownik","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R22-19-20210404","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MIB.0000000000001025","article-title":"Factors associated with discontinuation of anti-TNF inhibitors among persons with IBD: a population-based analysis.","volume":"23","author":"Targownik","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R23-19-20210404","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohns diseasea SONIC post hoc analysis.","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-19-20210404","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of Crohns disease.","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"key":"R25-19-20210404","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohns disease.","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"R26-19-20210404","first-page":"CD002095","article-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.","volume":"3","author":"van Pinxteren","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R27-19-20210404","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"R28-19-20210404","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R29-19-20210404","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R30-19-20210404","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease.","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"R31-19-20210404","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1155\/2013\/280860","article-title":"The utility of thiopurine methyl-transferase enzyme testing in inflammatory bowel disease.","volume":"27","author":"Chisick","year":"2013","journal-title":"Can J Gastroenterol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0108-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0108-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0108-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201808000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:46:17Z","timestamp":1786542377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201808000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1038\/s41395-018-0108-6","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}